newsfilter
← Latest News
Business Wire·

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

  • Maravai LifeSciences Holdings, Inc. secured a new credit agreement comprising a $150 million term loan facility & a $30 million revolving credit facility.
  • Borrowings from the new term loan & approximately $98.5 million in cash on hand were used to prepay outstanding debt under the prior credit agreement due in October 2027.
  • The transaction reduced aggregate long-term debt from approximately $242.9 million to $150.0 million & extended the maturity date to June 2032.
  • CFO Raj Asarpota stated the refinancing reduces debt, extends maturity, & provides a flexible credit structure to support strategic priorities & future growth.
  • The company remains a global provider of life science reagents & services focused on nucleic acid synthesis & biologics safety testing.
  • Additional transaction details are available in the Company's filings with the U.S. Securities and Exchange Commission.